Second Annual Global Champions of Change Competition Winner

MMS has just concluded its second annual Global Champions of Change Competition (G3C), where colleagues from all MMS regions submitted innovative ideas based on our tradition of providing high-quality, efficient services to our clients to help discover and market life-changing medicines to patients around the world.  

Innovation is not new to MMS, we have designed our culture from the beginning to constantly strive for new and better ways to produce quality with efficiency. The G3C competition was created two years ago as a formal way to spark the sharing of innovative ideas from colleagues throughout the entire organization in a competitive but fun environment.  

This year’s G3C winner is Amanda Beaster, Senior Manager of Regulatory Strategy, for her submission of a tool to address labeling deficiencies in the pharmaceutical industry.  

The second-place winners are Audelia Munguia, Director of Safety Risk Management; Susan Mitcheson, Senior Safety Writer; Jeff Wiese, Technical Manager of Safety Writing; and Katrina O’Connor, Senior Medical Writer, for their submission aimed to enhance efficiencies and quality in aggregate reports.  

Thirty-one teams entered this year’s competition, and five teams were chosen to proceed to the final presentation round, with our global colleagues voting for the winner. All 31 entries are evaluated and considered for future implementation.  

Other submissions included ideas that included automation, improving processes, data visualization, supporting rare diseases, improving quality, and concepts relating to MMS technologies such as our TrialAssure Transparency Suite and Datacise.  

MMS believes that innovation comes directly from our colleagues at every level of the organization because those working in our services lines daily see the best opportunities for improvement, and are encouraged to bring those ideas forward. That’s why we often say that “innovation is a company sport”. The G3C competition is not the only time our colleagues can bring innovative ideas forward, and MMS colleagues are encouraged to submit their ideas for improvement throughout the year.   

We are so proud of our colleagues and the effort, energy, and excitement they exhibited during this competition and through their work on a daily basis.  

By Jim Balcom, Director of Partnerships and IT Governance 

Learn more and explore MMS career opportunities here.  

Contact us to speak with Jim Balcom to learn more about innovation.  

Suggested For You

perspectives

May 13th, 2026

Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)

perspectives

May 5th, 2026

A Statistician's Reflection: FDA Guidance on Limiting Crossover in Oncology Studies 

perspectives

April 27th, 2026

From Stigma to Signal: The Executive Order, CNPV Vouchers, and What Comes Next for Psychedelics

perspectives

April 20th, 2026

The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain

perspectives

April 15th, 2026

Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks

perspectives

April 8th, 2026

Four Pillars of My Success as a Clinical Trial Transparency Specialist

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development